As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Chronic Urticaria or Hives – pipeline landscape globally. Chronic Urticaria or Hives Pipeline Insight, 2023” report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
Urticaria is an itchy rash that appears on the skin. It may appear on one part of the body or be spread across large areas. Chronic urticaria is a mast cell-mediated condition characterized by the recurrent occurrence of urticaria and/or angioedema.
The welts that come with hives are caused by the release of immune system chemicals, such as histamine, into the bloodstream. The skin reaction may be triggered by heat or cold, sunlight, vibration, pressure on the skin, medical conditions, such as thyroid disease, infection, allergy, and cancer.
Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31266
Symptoms of chronic hives includes batches of welts (wheals) that can arise anywhere on the body, welts that might be red, purple, or skin colored. Welts that vary in size, change shape, and appear and fade repeatedly, Itchiness (pruritus), which can be intense, painful swelling (angioedema) around the eyes, cheeks, or lips.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Chronic Urticaria or Hives treatment such as CT-P39, Dupilumab, LOU064, TEV-45779, Tezepelumab and others. Key players involved in the development of therapies to treat Chronic Urticaria or Hives are Amgen, Celltrion, Novartis Pharmaceuticals, Sanofi, Teva Pharmaceuticals USA and others. Eight drugs are under late-stage Phase III clinical trials and Nine drugs are in Phase II clinical trials and some other drugs are under Phase I, Phase 0 and Preclinical stages of development.
In December 2022, Allakos announced the proof-of-concept results of Lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria.
Report Highlights
Global Insight Service’s, Chronic Urticaria or Hives – Drug Pipeline Landscape, 2023 report provides an overview of the Chronic Urticaria or Hives pipeline drugs. This report covers detailed insights on Chronic Urticaria or Hives drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Chronic Urticaria or Hives pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Key Players
- Allakos Inc
- Alvotech
- Amgen
- AstraZeneca
- Celldex Therapeutics
- Celltrion
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd
- GI Innovation
- GlaxoSmithKline
- Hangzhou Highlightll Pharmaceutical Co., Ltd
- KeifeRx LLC
- LEO Pharma
Purchase your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31266
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like –
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: [email protected]
Phone: +1-833-761-1700